ArticleMolecular medicine (Cambridge, Mass.)2026
Dehydrocorydaline treatment suppresses Th17 differentiation via the mTOR-mediated STAT3-RORγt signaling in systemic lupus erythematosus.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundRecent studies have demonstrated the pivotal role of pathogenic Th17 cells during the target organ damage in systemic lupus erythematosus (SLE). Therefore, identifying Th17-related precision therapeutic targets is essential for developing effective treatments.
methodsPotential targets of a novel alkaloid compound, Dehydrocorydaline (DHC), in SLE were investigated using integrated network pharmacology and molecular docking. The therapeutic efficacy of DHC was evaluated in vivo using a lupus-prone mouse model and in vitro via pathogenic Th17 polarization assays. Mechanistic studies were conducted using transcriptional analysis, cell thermal shift assay (CETSA), microscale thermophoresis (MST), and chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR).
resultsThis study demonstrates the therapeutic potential of DHC in SLE. Network pharmacology analysis identified mTOR signaling and Th17 cell polarization as key potential targets and pathways of DHC. In vivo, DHC treatment selectively reduced the frequencies of Th17 cells, inhibited serum IL-17A levels, restored glomerular filtration rate (GFR), and attenuated renal damage in lupus mice. Molecular docking, CETSA, and MST results suggested a direct interaction between DHC and mTOR. In vitro, DHC inhibited the phosphorylation of mTOR and STAT3 during pathogenic Th17 differentiation. Pharmacological activation of mTOR reversed the inhibitory effects of DHC on STAT3 activation and Th17 differentiation. Mechanistically, DHC blocked the mTOR-dependent STAT3 nuclear translocation and Rorc transcription during Th17 polarization.
conclusionDHC attenuates renal damage in SLE by suppressing the Th17 response via the mTOR/STAT3/RORγt axis. This finding represents a novel therapeutic strategy for addressing the unmet clinical needs in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.